- Advertising
- Asia
- Bangladesh
- Biological Inventions
- BRAND VALUATION
- China
- Comparative Advertisement
- Copyright
- Copyright Infringement
- Copyright Litigation
- Counterfeiting
- Covid
- Design
- Digital Marketing Rights
- DRM
- Geographical Indication
- India
- Indian Patents Act
- Indonesia
- Intellectual Property
- Interim Injunction
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- Japan
- Legal Issues
- Licensing
- Malaysia
- Myanmar
- NCLT
- NEPAL
- Net Neutrality
- News & Updates
- Office
- Patent Commercialisation
- Patent Cooperation Treaty
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Opposition
- Patent Prosecution
- Patent Rule Amendment
- Patent Term Extension
- Patents
- pharma
- Philippines
- Punitive Damages
- Section 3(D)
- section 64
- Singapore
- South-east Asia
- Technology
- Technology Transfer
- Thailand
- Trademark
- Trademark Litigation
- Uncategorized
- USPTO
- Vietnam
- WIPO
Analysing the Parliamentary Committee’s Recommendations on IPAB
The Central Government established the Intellectual Property Appellate Board (IPAB) on the 15th of September 2003. The Board was constituted exclusively for hearing appeals related to the registrar’s decisions as per the Trade Marks Act, 1999, Geographical Indications of Goods Act (Registration and Protection), 1999, Patents Act, 1970, and the Copyright Act, 1957. The Board … Continue reading Analysing the Parliamentary Committee’s Recommendations on IPAB
Read more »DelSiTech and Visus Therapeutics enter into Patent Licensing Arrangement
Recently, DelSiTech Ltd. (“DelSiTech”), a Finland-based drug delivery company entered into a patent licensing agreement over DelSiTech’s patents with Visus Therapeutics (“Visius”), a US-based company. This is a worldwide exclusive licensing agreement. Both companies are working on six development programs for eye care solutions targeting the management of ocular diseases of the back and front … Continue reading DelSiTech and Visus Therapeutics enter into Patent Licensing Arrangement
Read more »Analysing the Legality and Ethical Debates Surrounding Biological Patents
In today’s day and age, scientific innovations are developing at a breakneck speed. A lion’s share of this development is facilitated by the biotechnology sector. In a broad sense, biotechnology can be defined as an area in biology that uses biological elements and living organisms to create products for commercial purposes. Such products may include … Continue reading Analysing the Legality and Ethical Debates Surrounding Biological Patents
Read more »ERS Genomics Licenses CRISPR-Cas9 patent and technology to Cellular Engineering Technologies
Recently, Dublin, Ireland-based biotechnology company, ERS Genomics Limited (“ERS”), has signed a nonexclusive license agreement with Iowa-based Cellular Engineering Technologies (“CET”) to grant access to its CRISPR-Cas9 patent portfolio. The financial terms of the agreement were not disclosed. ERS was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property for use as a … Continue reading ERS Genomics Licenses CRISPR-Cas9 patent and technology to Cellular Engineering Technologies
Read more »The Relevance of a Non-Disclosure Agreement in Protecting Your Intellectual Property
A Non-Disclosure Agreement (NDA) plays a pivotal role in various corporate transactions, employment agreements, negotiations or any other scenario wherein confidential information is being exchanged. In other words, it is a contract that enforces a confidential relationship between two or more parties wherein an agreement is made that any sensitive information that is made privy … Continue reading The Relevance of a Non-Disclosure Agreement in Protecting Your Intellectual Property
Read more »Compulsory Licensing in India Amidst the COVID 19 Pandemic: Will India Consider it?
The COVID-19 pandemic has truly exposed the frailty of our infrastructural systems. Innovation has taken a front seat and the world is keenly awaiting the public distribution of COVID-19 vaccines which would help restore normalcy. Among the numerous factors that were taken into consideration by global experts with respect to the COVID 19 vaccines, accessibility … Continue reading Compulsory Licensing in India Amidst the COVID 19 Pandemic: Will India Consider it?
Read more »Premas Biotech and Oravax enter into licensing deal for commercialization of VLP injectable vaccine technology in India
Recently, Oravax Medical Inc., (“Oravax” has entered into a licensing agreement with Premas Biotech to make available for commercialization of Oravax’s virus-like particle (VLP) vaccine technology. Oravax is a joint venture between Oramed Pharmaceuticals Inc., a US-based company (the majority shareholder), and Gurugram, India-based life sciences company, Premas Biotech (“Premas”). While the terms of the … Continue reading Premas Biotech and Oravax enter into licensing deal for commercialization of VLP injectable vaccine technology in India
Read more »Role of Intellectual Property Rights in Micro, Small and Medium Enterprises (MSMEs)
Micro, Small, and Medium Enterprises (MSMEs) play a pivotal role in India’s economy. Today, the supply chain for products and services is largely dependent on MSMEs. As a result, MSMEs generate employment on an enormous scale while facilitating the modernization and industrialization of rural areas in India. Upon recognizing the cruciality of MSMEs for the … Continue reading Role of Intellectual Property Rights in Micro, Small and Medium Enterprises (MSMEs)
Read more »Converse Wins Shoe Design Patent Claim against Steve Madden
Recently, the United States District Court of Massachusetts denied Steve Madden’s petition to dismiss part of the design patent infringement claim raised by Converse Inc. Steve Madden (“Madden”) is a major manufacturer and retailer of apparel, footwear, belts, handbags, and accessories, while Converse Inc., (“Converse”) is a major footwear company. Converse filed a suit complaining … Continue reading Converse Wins Shoe Design Patent Claim against Steve Madden
Read more »